Crescent Biopharma (CBIO) FDA Approvals $17.09 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$17.11 +0.02 (+0.15%) As of 07/2/2026 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Crescent Biopharma's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Crescent Biopharma (CBIO). Over the past two years, Crescent Biopharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CR-001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CR-001 FDA Regulatory Events CR-001 is a drug developed by Crescent Biopharma for the following indication: Treatment of Advanced Solid Tumors. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Poster Presentation - May 21,2026Poster Presentation Drug: CR-001Announced Date: May 21, 2026Indication: Treatment of Advanced Solid TumorsAnnouncementCrescent Biopharma, Inc. announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago.AI SummaryCrescent Biopharma announced that a trial-in-progress poster for its ASCEND study of CR-001 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2. CR-001 is a PD-1 x VEGF bispecific antibody being studied in a global Phase 1/2 trial across several solid tumors, including non-small cell lung cancer, gastrointestinal cancers, and gynecological cancers. The study includes both first-line and previously treated patients. The company said it expects multiple CR-001 data readouts starting in the first quarter of 2027. Crescent also noted that, through a strategic collaboration, Sichuan Kelun-Biotech has exclusive rights to develop and commercialize CR-001 in Greater China. Kelun-Biotech plans to begin its own Phase 1/2 trial of CR-001 in China in the first half of 2026.Read AnnouncementDose Update - February 18,2026Dose Update Phase 1/2Drug: CR-001Announced Date: February 18, 2026Indication: Treatment of Advanced Solid TumorsAnnouncementCrescent Biopharma, Inc. announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical trial evaluating CR-001, an investigational PD-1 x VEGF bispecific antibody, for the treatment of advanced solid tumors.AI SummaryCrescent Biopharma announced the first patient has been dosed in its global ASCEND Phase 1/2 trial testing CR-001, an investigational PD-1 x VEGF bispecific antibody, in advanced solid tumors. The study will evaluate CR-001 in multiple tumor types, including non-small cell lung cancer (NSCLC) and gastrointestinal and gynecological cancers, in both first-line and previously treated patients. ASCEND is the first of four clinical trials Crescent expects to start across its portfolio in 2026. The company plans to report proof-of-concept data in the first quarter of 2027. Results will include initial safety, pharmacokinetics, pharmacodynamics and preliminary antitumor activity from dose-escalation and backfill cohorts. CR-001, also known as SKB118, was discovered by Paragon Therapeutics. Under a strategic collaboration, Crescent has granted Sichuan Kelun-Biotech exclusive rights to develop and commercialize CR-001 in Greater China.Read Announcement Crescent Biopharma FDA Events - Frequently Asked Questions Has Crescent Biopharma received FDA approval? As of now, Crescent Biopharma (CBIO) has not received any FDA approvals for its therapy in the last two years. What drugs has Crescent Biopharma submitted to the FDA? In the past two years, Crescent Biopharma (CBIO) has reported FDA regulatory activity for CR-001. What is the most recent FDA event for Crescent Biopharma? The most recent FDA-related event for Crescent Biopharma occurred on May 21, 2026, involving CR-001. The update was categorized as "Poster Presentation," with the company reporting: "Crescent Biopharma, Inc. announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago." What conditions do Crescent Biopharma's current drugs treat? Currently, Crescent Biopharma has one therapy (CR-001) targeting the following condition: Treatment of Advanced Solid Tumors. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events HUTCHMED FDA EventsRevolution Medicines FDA EventsArtelo Biosciences FDA EventsBiogen FDA EventsNeurocrine Biosciences FDA EventsNLS Pharmaceutics FDA EventsVertex Pharmaceuticals FDA EventsAC Immune FDA EventsAptevo Therapeutics FDA EventsHeartBeam FDA EventsCandel Therapeutics FDA EventsCogent Biosciences FDA EventsDesign Therapeutics FDA EventsMoleculin Biotech FDA EventsNovoCure FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Innoviva FDA Events Zenas BioPharma FDA Events Novavax FDA Events MannKind FDA Events Lexicon Pharmaceuticals FDA Events OPKO Health FDA Events Geron FDA Events Rigel Pharmaceuticals FDA Events Ironwood Pharmaceuticals FDA Events Achieve Life Sciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CBIO last updated on 5/22/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersGoldman Sachs: 300 million jobs will disappearGoldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is ac...InvestorPlace | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredWorld’s Largest Investors Are Moving Their Money (Not Into AI)While headlines focus on the next AI IPO, the world's largest investors are moving capital into one asset at t...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Poster Presentation - May 21,2026Poster Presentation Drug: CR-001Announced Date: May 21, 2026Indication: Treatment of Advanced Solid TumorsAnnouncementCrescent Biopharma, Inc. announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago.AI SummaryCrescent Biopharma announced that a trial-in-progress poster for its ASCEND study of CR-001 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2. CR-001 is a PD-1 x VEGF bispecific antibody being studied in a global Phase 1/2 trial across several solid tumors, including non-small cell lung cancer, gastrointestinal cancers, and gynecological cancers. The study includes both first-line and previously treated patients. The company said it expects multiple CR-001 data readouts starting in the first quarter of 2027. Crescent also noted that, through a strategic collaboration, Sichuan Kelun-Biotech has exclusive rights to develop and commercialize CR-001 in Greater China. Kelun-Biotech plans to begin its own Phase 1/2 trial of CR-001 in China in the first half of 2026.Read Announcement
Dose Update - February 18,2026Dose Update Phase 1/2Drug: CR-001Announced Date: February 18, 2026Indication: Treatment of Advanced Solid TumorsAnnouncementCrescent Biopharma, Inc. announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical trial evaluating CR-001, an investigational PD-1 x VEGF bispecific antibody, for the treatment of advanced solid tumors.AI SummaryCrescent Biopharma announced the first patient has been dosed in its global ASCEND Phase 1/2 trial testing CR-001, an investigational PD-1 x VEGF bispecific antibody, in advanced solid tumors. The study will evaluate CR-001 in multiple tumor types, including non-small cell lung cancer (NSCLC) and gastrointestinal and gynecological cancers, in both first-line and previously treated patients. ASCEND is the first of four clinical trials Crescent expects to start across its portfolio in 2026. The company plans to report proof-of-concept data in the first quarter of 2027. Results will include initial safety, pharmacokinetics, pharmacodynamics and preliminary antitumor activity from dose-escalation and backfill cohorts. CR-001, also known as SKB118, was discovered by Paragon Therapeutics. Under a strategic collaboration, Crescent has granted Sichuan Kelun-Biotech exclusive rights to develop and commercialize CR-001 in Greater China.Read Announcement
